VNRX - VolitionRX Ltd Stock Price, Fair Value and News

0.89USD+0.01 (+1.14%)Delayed

Market Summary

USD0.89+0.01

Delayed

1.14%

VNRX Stock Price

View Fullscreen

VNRX RSI Chart

VNRX Valuation

Market Cap

73.0M

Price/Earnings (Trailing)

-2.05

Price/Sales (Trailing)

340.59

Price/Free Cashflow

-3.81

VNRX Price/Sales (Trailing)

VNRX Profitability

Return on Equity

409.51%

Return on Assets

-127.64%

Free Cashflow Yield

-26.21%

VNRX Fundamentals

VNRX Revenue

Revenue (TTM)

214.5K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

VNRX Earnings

Earnings (TTM)

-35.7M

Earnings Growth (Yr)

-19.95%

Earnings Growth (Qtr)

-4.1%

Breaking Down VNRX Revenue

Last 7 days

-2.2%

Last 30 days

18.7%

Last 90 days

-17.6%

Trailing 12 Months

-55.9%

How does VNRX drawdown profile look like?

VNRX Financial Health

Current Ratio

0.69

Debt/Equity

-0.42

Debt/Cashflow

-4.98

VNRX Investor Care

Shares Dilution (1Y)

30.07%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.3M	944.7K	821.9K	214.5K
2022	1.6M	1.6M	1.4M	1.3M
2021	880.1K	1.1M	1.3M	1.5M
2020	193.4K	284.4K	267.3K	666.0K
2019	0	0	31.9K	169.8K
2014	0	0	54.1K	42.4K
2012	197.3K	191.0K	197.5K	55.0K
2011	0	0	0	208.1K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of VolitionRX Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	butera salvatore thomas	sold (taxes)	-13,488	0.87	-15,504	ceo, volition veterinary
Jan 24, 2024	henshall mickie	acquired	-	-	8,500	-
Jan 24, 2024	michel gaetan	acquired	-	-	42,925	chief operating officer
Jan 24, 2024	micallef jacob vincent	acquired	-	-	23,375	chief scientific officer
Jan 24, 2024	forterre gael	acquired	-	-	25,925	chief commercial officer
Jan 24, 2024	batchelor ann-louise	acquired	-	-	22,525	group chief marketing officer
Jan 24, 2024	colman alan	acquired	-	-	8,500	-
Jan 24, 2024	futcher edward	acquired	-	-	8,500	-
Jan 24, 2024	barnes phillip	acquired	-	-	8,500	-
Jan 24, 2024	reynolds cameron john	acquired	-	-	50,150	president and ceo

Which funds bought or sold VNRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	unchanged	-	11.00	201	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	8.00	152	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	-	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-15,020	-	-%
Apr 24, 2024	Hartford Financial Management Inc.	unchanged	-	200	3,785	-%
Apr 23, 2024	Spectrum Asset Management, Inc. (NB/CA)	unchanged	-	2,224	42,087	0.02%
Apr 11, 2024	Silverberg Bernstein Capital Management LLC	reduced	-1.65	4,050	109,476	0.11%
Apr 10, 2024	Founders Capital Management	unchanged	-	80.00	1,514	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	215	215	-%

Are Funds Buying or Selling VNRX?

Are funds buying VNRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VNRX

No. of Funds

Unveiling VolitionRX Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lagoda investment management, l.p.	4.7%	3,728,600	SC 13G/A
Feb 09, 2024	reynolds cameron john	3.5%	2,868,465	SC 13D/A
Feb 14, 2023	lagoda investment management, l.p.	6.53%	3,755,045	SC 13G/A
Feb 14, 2022	lagoda investment management, l.p.	6.1%	3,283,913	SC 13G/A
Mar 01, 2021	reynolds cameron john	5.1%	2,674,167	SC 13D/A
Mar 01, 2021	faulkes martin charles	4.2%	2,236,943	SC 13D/A
Mar 01, 2021	innes guy archibald	3.7%	1,925,701	SC 13D/A
Feb 16, 2021	lagoda investment management, l.p.	5.3%	2,547,481	SC 13G
Jul 09, 2020	eight corp ltd	25.9%	11,976,263	SC 13D/A
Jun 10, 2020	eight corp ltd	23.8%	12,045,332	SC 13D/A

Recent SEC filings of VolitionRX Ltd

View All Filings

Date Filed	Form Type	Document
May 03, 2024	4	Insider Trading
Apr 26, 2024	8-K	Current Report
Apr 26, 2024	PRE 14A	PRE 14A
Mar 26, 2024	D	D
Mar 25, 2024	10-K	Annual Report
Mar 25, 2024	8-K	Current Report
Mar 22, 2024	3	Insider Trading
Mar 19, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to VolitionRX Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	183.9B	23.7B	1.64%	2.48%	41.79	7.75	-8.94%	-35.72%
A	40.9B	6.7B	-2.98%	4.15%	33.06	6.07	-2.81%	-6.58%
IDXX	39.7B	3.7B	-8.30%	2.34%	45.8	10.65	8.57%	23.94%
DGX	15.3B	9.3B	3.82%	1.51%	18.05	1.64	-3.29%	6.68%
MEDP	12.2B	2.0B	-0.85%	91.42%	38.94	6.2	25.57%	21.62%
CRL	12.0B	4.1B	-9.98%	23.20%	25.25	2.9	3.86%	-2.39%
NTRA	11.7B	1.1B	4.72%	83.22%	-26.93	10.82	31.99%	20.63%
EXAS	11.3B	2.5B	-14.71%	-5.54%	-55.23	4.51	19.93%	67.26%
MID-CAP
NEOG	2.6B	929.2M	-15.71%	-30.96%	1.7K	2.8	28.93%	111.61%
GH	2.3B	563.9M	-4.01%	-17.46%	-4.8	4.08	25.45%	26.76%
SMALL-CAP
CDNA	502.8M	280.3M	-3.29%	12.78%	-2.64	1.79	-12.89%	-148.37%
ACRS	95.7M	31.2M	8.00%	-84.75%	-1.08	3.06	5.03%	-1.81%
APDN	63.7M	9.0M	754.55%	265.05%	-8.81	7.08	-53.31%	2.21%
AWH	39.6M	9.2M	14.64%	-28.67%	-2.37	4.33	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

VolitionRX Ltd News

Latest updates

VolitionRX Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2014Q4	2014Q3	2012Q4
Revenue	-100.0%	-	49.00	-	166	607	171	393	114	712	419	392	464	537	-	91.00	38.00	138	17.00	-	15.00	-
Operating Expenses	1.9%	8,985	8,818	9,765	9,195	8,130	8,026	8,139	7,791	8,799	7,588	5,925	6,111	5,666	4,505	5,218	5,872	3,725	4,193	-	-	-
S&GA Expenses	21.1%	1,899	1,568	1,669	1,707	1,678	1,525	1,774	1,599	1,858	837	562	427	339	245	216	274	248	196	-	-	-
R&D Expenses	-2.3%	4,544	4,651	5,451	4,906	4,296	4,002	3,279	3,590	2,951	3,612	2,936	3,873	3,966	3,180	3,493	3,895	2,767	2,643	-	-	-
Interest Expenses	7.4%	58.00	54.00	58.00	51.00	57.00	38.00	37.00	41.00	35.00	39.00	40.00	42.00	39.00	35.00	23.00	34.00	61.00	32.00	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-1*	-	-	-	-	-	-	-	-
Net Income	-4.1%	-8,799	-8,453	-9,551	-8,872	-7,336	-7,812	-7,732	-7,718	-8,108	-7,181	-5,574	-6,125	-5,160	-4,335	-5,043	-5,859	-3,557	-4,180	-	-	-
Net Income Margin	-299.6%	-166.36*	-41.63*	-35.54*	-23.73*	-23.78*	-22.56*	-18.76*	-17.46*	-17.73*	-18.38*	-19.37*	-23.48*	-	-	-	-	-	-	-	-	-
Free Cashflow	170.6%	6,139	-8,691	-7,648	-8,945	-6,382	-7,144	-6,806	3,486	-4,537	-5,020	-5,620	-6,649	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	54.9%	27,950	18,041	27,561	18,044	18,295	23,341	24,347	31,683	27,490	30,004	35,244	40,510	26,151	26,088	26,247	16,875	21,291	23,777	22,881	20,631	17,489
Current Assets	79.2%	21,854	12,197	21,507	11,958	12,172	17,674	18,649	25,957	21,979	24,418	29,392	34,669	20,332	22,165	22,419	13,101	17,556	20,307	19,244	17,072	13,902
Cash Equivalents	91.8%	20,730	10,809	19,743	10,011	10,867	16,416	16,730	23,732	20,581	22,902	27,913	33,062	19,445	20,928	21,305	11,970	16,966	19,697	18,511	16,166	13,427
Net PPE	4.1%	5,523	5,305	5,455	5,402	5,393	4,881	4,808	4,721	4,911	5,081	5,267	5,249	5,171	3,343	3,265	3,097	2,981	2,890	3,038	3,025	3,120
Liabilities	75.5%	36,663	20,892	22,443	21,025	21,422	20,502	20,268	20,873	9,768	8,823	8,614	9,347	9,857	7,126	7,583	7,690	7,093	5,975	6,498	5,520	5,349
Current Liabilities	80.3%	31,837	17,654	18,803	17,238	17,386	16,978	17,351	17,513	6,516	5,852	5,398	6,000	6,237	4,318	4,708	4,634	3,860	3,243	3,497	2,666	2,333
Long Term Debt	73.8%	3,625	2,086	2,452	2,549	2,779	2,275	1,743	2,032	2,271	2,028	2,220	2,391	2,607	1,831	1,914	2,063	2,195	1,732	3,001	1,797	1,984
LT Debt, Current	-4.1%	1,207	1,258	1,199	1,121	1,067	1,065	1,085	1,333	798	760	822	841	841	765	693	613	648	-	563	-	417
LT Debt, Non Current	73.8%	3,625	2,086	2,452	2,549	2,779	2,275	1,743	2,032	2,271	2,028	2,220	2,391	2,607	1,831	1,914	2,063	2,195	1,732	1,956	1,797	1,984
Shareholder's Equity	-Infinity%	-8,712	-	5,118	-	-3,126	2,840	4,079	10,811	17,722	21,181	26,630	31,163	16,294	18,961	18,663	9,185	14,199	17,802	16,383	15,111	12,140
Retained Earnings	-4.5%	-202,576	-193,878	-185,507	-176,036	-167,257	-160,015	-152,272	-144,622	-136,988	-128,953	-121,817	-116,290	-110,173	-105,036	-100,708	-95,681	-89,821	-86,264	-82,083	-77,926	-73,722
Additional Paid-In Capital	1.5%	194,448	191,518	191,065	173,467	164,397	162,940	156,442	155,655	154,731	150,221	148,468	147,382	126,526	124,122	118,916	104,326	103,854	103,374	98,178	92,800	85,604
Shares Outstanding	4.5%	81,898	78,342	78,136	63,112	57,873	57,496	53,847	53,790	53,772	53,224	53,144	52,871	-	-	-	-	-	-	-	-	-
Minority Interest	-12.5%	-909	-808	-725	-645	-551	-	-388	-	-222	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	82,182	-	-	-	73,353	-	-	-	115,639	-	-	-	111,768	-	-	-	72,468	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	176.6%	6,448	-8,418	-7,347	-8,744	-5,803	-6,819	-6,265	3,610	-4,409	-4,878	-5,401	-6,165	-2,734	-4,499	-4,430	-4,798	-2,598	-3,717	-2,772	-3,650	-3,629
Share Based Compensation	-13.4%	466	538	592	694	706	639	854	915	-	768	-	-	530	308	388	165	368	371	382	338	695
Cashflow From Investing	-13.1%	-308	-273	-301	-200	-578	-325	-541	-124	-128	-141	-219	-483	-1,065	15.00	-266	-330	-151	-122	-124	-112	-118
Cashflow From Financing	1472.3%	3,770	-274	17,340	8,147	926	6,727	-460	-254	2,097	51.00	501	20,208	2,139	4,601	14,082	-202	535	4,638	5,187	6,570	633
Buy Backs	-	-	-	-	32.00	-	-	-	-	-	-	-	-	-	-	-	-54.43	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VNRX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues
Royalty	$ 1,369	$ 2,911
Service	175,476	92,488
Product	598,457	210,993
Total Revenues	775,302	306,392
Operating Expenses
Research and development	19,551,523	15,332,989
General and administrative	10,368,314	10,177,229
Sales and marketing	6,843,160	6,576,246
Total Operating Expenses	36,762,997	32,086,464
Operating Loss	(35,987,695)	(31,780,072)
Other Income (Expenses)
Grant income	214,451	1,229,425
Loss on disposal of fixed assets	(15,843)	0
Interest income	93,324	125,265
Interest expense	(221,622)	(173,087)
Gain on change in fair value of warrant liability	240,311	0
Total Other Income	310,621	1,181,603
Net Loss	(35,677,074)	(30,598,469)
Net Loss attributable to Non-Controlling Interest	357,996	329,676
Net Loss attributable to VolitionRx Limited Stockholders	(35,319,078)	(30,268,793)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	16,843	78,771
Net Comprehensive Loss	$ (35,660,231)	$ (30,519,698)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited Stockholders	$ (0.50)	$ (0.55)
Weighted Average Shares Outstanding
- Basic and Diluted	71,234,565	55,350,401

VNRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 20,729,983	$ 10,867,050
Accounts receivable	242,617	72,609
Prepaid expenses	521,370	784,920
Other current assets	360,125	447,566
Total Current Assets	21,854,095	12,172,145
Property and equipment, net	5,523,013	5,393,012
Operating lease right-of-use assets	549,504	619,392
Intangible assets, net	23,886	110,505
Total Assets	27,950,498	18,295,054
Current Liabilities
Accounts payable	3,211,287	3,043,008
Accrued liabilities	3,928,761	2,872,247
Deferred revenue	23,000,000	10,000,000
Management and directors' fees payable	59,625	71,119
Current portion of long-term debt	1,207,007	1,066,700
Warrant liability	126,649	0
Current portion of financing lease liabilities	48,570	46,014
Current portion of operating lease liabilities	199,323	245,163
Current portion of grant repayable	55,855	41,836
Total Current Liabilities	31,837,077	17,386,087
Long-term debt, net of current portion	3,624,860	2,779,240
Finance lease liabilities, net of current portion	400,022	436,132
Operating lease liabilities, net of current portion	378,054	400,091
Grant repayable, net of current portion	422,707	420,466
Total Liabilities	36,662,720	21,422,016
Stockholders' Deficit
Common stock Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 81,898,321 shares and 57,873,379 shares, respectively	81,898	57,873
Additional paid-in capital	194,448,414	164,397,468
Accumulated other comprehensive income	243,940	227,097
Accumulated deficit	(202,576,507)	(167,257,429)
Total VolitionRx Limited Stockholders' Deficit	(7,802,255)	(2,574,991)
Non-controlling interest	(909,967)	(551,971)
Total Stockholders' Deficit	(8,712,222)	(3,126,962)
Total Liabilities and Stockholders' Deficit	$ 27,950,498	$ 18,295,054

About VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.

CEO	Mr. Cameron Reynolds MBA
WEBSITE	https://volition.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	111

VolitionRX Ltd Frequently Asked Questions

What is the ticker symbol for VolitionRX Ltd? What does VNRX stand for in stocks?

VNRX is the stock ticker symbol of VolitionRX Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of VolitionRX Ltd (VNRX)?

As of Fri May 03 2024, market cap of VolitionRX Ltd is 73.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VNRX stock?

You can check VNRX's fair value in chart for subscribers.

What is the fair value of VNRX stock?

You can check VNRX's fair value in chart for subscribers. The fair value of VolitionRX Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of VolitionRX Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VNRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is VolitionRX Ltd a good stock to buy?

The fair value guage provides a quick view whether VNRX is over valued or under valued. Whether VolitionRX Ltd is cheap or expensive depends on the assumptions which impact VolitionRX Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VNRX.

What is VolitionRX Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, VNRX's PE ratio (Price to Earnings) is -2.05 and Price to Sales (PS) ratio is 340.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VNRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on VolitionRX Ltd's stock?

In the past 10 years, VolitionRX Ltd has provided -0.079 (multiply by 100 for percentage) rate of return.